Welcome to our dedicated page for Surgalign Holdings news (Ticker: SRGA), a resource for investors and traders seeking the latest updates and insights on Surgalign Holdings stock.
Surgalign Holdings, Inc. (SRGA) is a prominent medical technology company that specializes in the design, development, manufacture, and distribution of biologic, metal, and synthetic implants worldwide. Established in 1997 and headquartered in Deerfield, Illinois, Surgalign Holdings has carved out a significant niche in the fields of orthopedics, spine, sports medicine, plastic surgery, trauma, and other surgical procedures.
The company offers a range of innovative products aimed at improving surgical outcomes and promoting natural healing. Among its key offerings is the Coflex Interlaminar Stabilization Device, which is designed to treat moderate to severe lumbar spinal stenosis in conjunction with decompression. Additionally, the Simmetry Sacroiliac Joint Fusion System is known to decrease opioid use, pain, and disability. Another notable product is the Fortilink IBF System with TETRAfuse 3D technology, enhancing the integration and fusion of spinal implants.
Surgalign’s state-of-the-art implants are utilized by healthcare providers, hospitals, and various healthcare facilities through a robust distribution network. The company leverages its direct distribution force, OEM relationships, and an extensive network of independent distributors to reach its clients effectively. Surgalign's commitment to quality and innovation has positioned it as a leader in medical technology, dedicated to enhancing patient outcomes and advancing the field of surgical implants.
For more information, the latest updates, and media inquiries, please contact Glenn Wiener at gwiener@gwcco.com or +1 917 887 8434.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced the grant of restricted stock unit awards to 11 new employees as an employment inducement. The awards, totaling 543,380 shares, were granted on March 1, 2022, under the 2021 Inducement Plan. Vesting occurs in thirds over three years, with one-third vesting on the first anniversary and the remainder vesting quarterly thereafter. The awards were approved by the independent Compensation Committee and adhere to Nasdaq regulations.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced a public offering of 43,478,264 shares of common stock at an effective price of $0.46 per share, along with warrants to purchase 32,608,698 additional shares. The offering aims to raise approximately $20 million, intended for working capital and the development of digital health solutions. The deal is expected to close around February 15, 2022, pending customary conditions. An underwriter option allows for an additional purchase of shares and warrants. H.C. Wainwright & Co. serves as the book-running manager.
Surgalign Holdings, Inc. (NASDAQ: SRGA) has announced plans to offer and sell shares of its common stock and warrants in an underwritten public offering, subject to market conditions. The company has appointed H.C. Wainwright & Co. as the lead underwriter and expects to grant them a 30-day option for additional shares. The net proceeds will be utilized for working capital and further development of digital health offerings. A preliminary prospectus will be filed with the SEC, and this offering is not an offer to sell securities in any jurisdiction where it would be unlawful.
Surgalign Holdings, Inc. (NASDAQ: SRGA) recently announced the granting of restricted stock unit awards to nine new employees, totaling up to 257,695 shares of common stock. These awards, effective February 1, 2022, are part of the 2021 Inducement Plan, with vesting occurring over three years. The awards aim to attract talent and were approved by the independent Compensation Committee under Nasdaq rules. Surgalign focuses on digital health solutions to enhance surgical outcomes and operates in over 50 countries, headquartered in Deerfield, IL.
Surgalign Holdings, Inc. (NASDAQ: SRGA) received FDA 510(k) clearance for its HOLO Portal surgical guidance system, marking a significant advancement in the lumbar spine surgery segment of the $5 billion instrumented fusion market. This AI-driven system integrates augmented reality for enhanced surgical guidance. The company anticipates generating preliminary global revenues between $21.5 million and $21.9 million for Q4 2021, and between $90.2 million and $90.6 million for the full year 2021, with $51 million in cash reserves.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced participation in the Sidoti Virtual Small Cap Conference on January 20, 2022. The management team will engage in a fireside chat scheduled for 11:30 a.m. Eastern Time, available via webcast on the company's investor relations page.
As a global medical technology company, Surgalign focuses on advancing digital health solutions to improve surgical outcomes worldwide. A replay of the webcast will be archived on their website.
Surgalign Holdings announced the grant of restricted stock unit awards to twelve new employees, totaling 339,241 shares of common stock. This inducement, effective January 3, 2022, is part of the 2021 Inducement Plan. Vesting occurs in stages, with one-third vesting on the first anniversary and the remainder vesting quarterly, fully vesting by the third anniversary, contingent on continued employment.
The awards were approved by the independent Compensation Committee, aimed at enhancing recruitment under Nasdaq regulations.
Surgalign Holdings, Inc. (NASDAQ: SRGA) has acquired a 42% equity interest in Inteneural Networks Inc. for $21 million, enhancing its AI capabilities in medical imaging. This acquisition enables Surgalign to integrate INN's technology, which autonomously identifies and segments neural structures. Future acquisition of the remaining 58% is contingent on achieving certain commercial milestones. The deal is a strategic move to expand Surgalign's digital health platform beyond spine surgery.
Surgalign Holdings, a global medical technology company (NASDAQ: SRGA), announced its participation in the 2022 H.C. Wainwright Virtual BioConnect Conference from January 10-13, 2022. A recording of the presentation will be available on January 10, 2022, at 7 AM ET on the company's investor relations page. Surgalign is committed to enhancing surgical standards through digital surgery and operates in over 50 countries, focusing on improved clinical outcomes for patients.
Surgalign Holdings granted restricted stock unit awards to three new employees, totaling up to 24,000 shares, effective December 1, 2021. These awards are part of the 2021 Inducement Plan and will vest over three years, contingent on continued employment. Approved by the Compensation Committee, the awards aim to incentivize new hires. Surgalign is focused on advancing digital surgery technology for improved patient outcomes, operating globally with a network of distributors.
FAQ
What does Surgalign Holdings, Inc. specialize in?
Where is Surgalign Holdings, Inc. headquartered?
What are some key products offered by Surgalign Holdings, Inc.?
How does Surgalign distribute its products?
In which medical fields are Surgalign’s implants used?
When was Surgalign Holdings, Inc. founded?
What is the purpose of the Coflex Interlaminar Stabilization Device?
How does the Simmetry Sacroiliac Joint Fusion System benefit patients?
What technology does the Fortilink IBF System utilize?
Who should be contacted for media inquiries about Surgalign Holdings, Inc.?
